NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis $1.44 +0.08 (+5.88%) Closing price 04:00 PM EasternExtended Trading$1.42 -0.01 (-1.04%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Geron Stock (NASDAQ:GERN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Geron alerts:Sign Up Key Stats Today's Range$1.36▼$1.4650-Day Range$1.10▼$1.6552-Week Range$1.04▼$2.01Volume11.31 million shsAverage Volume14.06 million shsMarket Capitalization$923.79 millionP/E RatioN/ADividend YieldN/APrice Target$2.50Consensus RatingHold Company Overview Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options. The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. Imetelstat works by directly binding to the RNA template of telomerase, thereby blocking the enzyme’s activity and shortening telomeres in malignant cells. Preclinical studies have also explored potential applications of telomerase inhibition in various solid tumors. Founded in 1990 by researchers Elizabeth Blackburn, Carol Greider and Jack Szostak—who later received the Nobel Prize in Physiology or Medicine for their work on telomeres—Geron is headquartered in Foster City, California. The company has established collaborations and licensing agreements with academic institutions, contract research organizations and pharmaceutical partners to advance its clinical programs and expand its research capabilities. Under the leadership of CEO John A. Scarlett, Geron continues to build its infrastructure for late-stage clinical development. The company serves a global community of physicians, researchers and patients by conducting multi-center clinical trials across North America and Europe, with the goal of bringing telomerase-targeted therapies to market.AI Generated. May Contain Errors. Read More Geron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreGERN MarketRank™: Geron scored higher than 29% of companies evaluated by MarketBeat, and ranked 702nd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingGeron has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 2 sell ratings.Upside PotentialGeron has a consensus price target of $2.50, representing about 73.6% upside from its current price of $1.44.Amount of Analyst CoverageGeron has only been the subject of 1 research reports in the past 90 days.Read more about Geron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.02) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -13.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -13.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.87% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 5.89.Change versus previous monthShort interest in Geron has recently increased by 4.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Geron this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows6 people have added Geron to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by Insiders1.71% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GERN Stock News HeadlinesGeron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-UpJuly 1, 2026 | seekingalpha.comGeron Corporation (NASDAQ:GERN) Given Average Recommendation of "Hold" by AnalystsJune 30, 2026 | americanbankingnews.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.July 6 at 1:00 AM | Porter & Company (Ad)Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 18, 2026 | globenewswire.comGeron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 1, 2026 | globenewswire.comGeron: Time To Reconsider This Oversold BiotechJune 1, 2026 | seekingalpha.comGeron Shareholders Expand Equity Plan and Elect DirectorsMay 27, 2026 | tipranks.comSee More Headlines GERN Stock Analysis - Frequently Asked Questions How have GERN shares performed this year? Geron's stock was trading at $1.32 at the start of the year. Since then, GERN shares have increased by 9.1% and is now trading at $1.44. How were Geron's earnings last quarter? Geron Corporation (NASDAQ:GERN) posted its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The biopharmaceutical company had revenue of $51.84 million for the quarter, compared to analysts' expectations of $50.59 million. Geron had a negative net margin of 35.48% and a negative trailing twelve-month return on equity of 23.31%. Read the conference call transcript. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings5/06/2026Today7/06/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 10 days, GERN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN Previous SymbolNASDAQ:GERN CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees70Year Founded1990Price Target and Rating Average Price Target for Geron$2.50 High Price Target$4.00 Low Price Target$1.00 Potential Upside/Downside+73.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.50 million Net Margins-35.48% Pretax Margin-34.32% Return on Equity-23.31% Return on Assets-10.08% Debt Debt-to-Equity Ratio0.52 Current Ratio6.78 Quick Ratio4.96 Sales & Book Value Annual Sales$183.88 million Price / Sales5.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book4.11Miscellaneous Outstanding Shares641,520,000Free Float630,551,000Market Cap$923.79 million OptionableOptionable Beta0.60 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:GERN) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
